Natural killer cells in human solid tumors

CANCER AND METASTASIS REVIEW

Volumn 2, Issue 4, 1983, Pages 337-350

  Introna, Martino ^a   Mantovani, Alberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON;

ANIMAL; BLOOD; CYTOTOXICITY; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE; MACROPHAGE; NATURAL KILLER CELL; NEOPLASM; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; INTERFERONS; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTES; MACROPHAGES; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0020997919     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00048566     Document Type: Article

References (106)

1. Natural cell-mediated immunity
2. Natural cytotoxic (NC) cells against solid tumors in mice: General characteristics and comparison to natural killer (NK) cells
3. Cytostasis of tumor cell lines by human granulocytes
4. Cytolytic and cytostatic activity on tumor cells of circulating human monocytes
5. Natural cytotoxicity on tumor cells of human monocytes and macrophages
6. Natural cytotoxicity of mouse monocytes and macrophages
7. Regulatory capacities of mononuclear phagocytes with particular reference to natural immunity against tumors
8. Promonocytes have the functional characteristics of natural killer cells
9. Natural cytotxic cells against solid tumors in mice. I. Strain and age distribution and target cell susceptibility
10. Natural cytotoxic cells against solid tumors in mice. II. Some characteristics of the effector cells
11. Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets
12. Human natural cell-mediated cytotoxicity against fetal fibroblasts. III. Morphological and functional characterization of the effector cells
13. Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity cell-line targets
14. Isolation of human NK cells by density gradient centrifugation
15. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells
16. Natural killer cells: Their role in defenses against disease
17. Do natural killer cells engage in regulated reactions against self to ensure homeostasis
18. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin
19. Cellular microcytotoxicity in human tumor systems: Analysis of results
20. Spontaneous human lymphocyte-mediated cytotoxicity against tumour target cells. I. The effect of malignant disease
21. Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells
22. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression
23. Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients
24. Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays
25. Serial monoclear cell cytotoxicity levels in breast cancer patients and normal controls
26. Systemic and in situ natural killer activity in tumor bearing mice and patients with cancer
27. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors
28. Tumor-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients
29. Natural killer cells in tumor-bearing patients
30. Natural cell-mediated cytotoxicity in human tumor patients
31. NK cell activity in the blood, tumor-draining lymph nodes and primary tumours of women with mammary carcinoma
32. Suppressor cells of immune reactivity in malignancy
33. Generation of suppressor cells for natural killer activity in cancer patients after surgery
34. Natural cytotoxicity in man: Activity of lymph node and tumor-infiltrating lymphocytes
35. The relationship between cytotoxicity and prognostically significant histologic changes in lymph-nodes from patients with cancer of the breast
36. Extravascular natural cytotoxicity in man-Anti-K562 activity of lymph-node and tumor-infiltrating lymphocytes
37. Natural killers in human cancer: Activity of tumor-infiltrating and draining node lymphocytes
38. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignat disease
39. Spontaneous cell-mediated cytotoxicity (SCMC) and antibody-dependent cellular cytotoxicity (ADCC) in peripheral blood and draining lymph nodes of patients with mammary carcinoma
40. Natural killer cells in carcinomatus pleural effusions
41. Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. (III). Further functional investigations using cultured autochthonous tumor cell lines and freeze-thawed infiltrating inflammatory cells
42. Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II. Functional investigations of the infiltrating inflammatory cells
43. Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumor and ascites-derived inflammatory cells
44. Quantitation of proliferative and cytotoxic precursor cells directed against human tumors: Limiting dilution analysis in peripheral blood and at the tumour site
45. Reduction of supressor cells in cancer patients treated with OK-432 immunotherapy
46. Development of cytotoxic cells during in vitro cultures of pleural effusion lymphocytes from patients with lung cancer
47. Suppression of natural killer cell activity by adherent cells in cancer patients after surgery
48. Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity
49. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours
50. Inhibition of natural killer activity by tumor-associated lymphoid cells from ascitic ovarian carcinomas
51. Do natural killer cells engage in regulated reaction against self to ensure homeostatsis
52. Inhibition as well as augmentation of mouse NK activity by pyran copolymer and adriamycin
53. Prostaglandin synthesis inhibitors potentiate the BCG-induced augmentation of natural killer cell activity
54. Natural killer activity in human ovarian tumors
55. Inhibition of natural killer activity by human vronchoalveolar macrophages
56. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1)
57. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice
58. Bonmasser mice
59. Immunologic evaluation of long-term effects of schildhood ALL chemotherapy: Analysis of in vitro NK- en K-cell activities of peripheral blood lymphocytes
60. Induction and kinetics of natural killer cells in humans following interferon therapy
61. Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon
62. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-α
63. Clinical and immunological studies of human fibroblast interferon
64. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell populations
65. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity
66. Effect of leukocyte interferon on natural killer cells in healthy volunteers
67. Modulation of NK activity by recombinant leukocyte interferon in advanced cancer patients
68. Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated macrophages and NK cells
69. Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngenic and allogeneic target cells
70. Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity
71. An Analysis of conditions allowing Corynebacterium parvum to cause either augmentation or inhibition of natural killer cell activity against tumour cells in mice
72. Factors affecting stimulation of natural cytotoxicity to a rat lymphoma by Corynebacterium parvum
73. Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma
74. Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy
75. Modulation of natural cytotoxicity in man by BCG and fibroblast interferon
76. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: A weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions
77. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytotoxicity and delayed hypersensitivity skin reactions
78. NK activity of lymphocytes infiltrating BCG-injected tumors. (Abstract)
79. Streptococcal preparation Ok-432 augments cytotoxic activity against an erythroleukemic cell line in humans
80. Augmentation of NK cell activity in cancer patients by OK432: Activation of NK cell activation of NK cells and reduction of suppressor cells
81. Association of human natural killer cell activity against human primary tumors with large granular lymphocytes
82. Natural cytotoxicity in humans: Susceptibility of freshly isolated tumor cells to lysis
83. Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphocytes
84. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells
85. Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans
86. Restricted autologous lymphocytotoicity in lung neoplasia
87. Activation of human natural killer cells cytotoxic for human leukemia cells by perified interferon
88. Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma
89. Interferon effect on cytoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells
90. Susceptibility of human leukaemias to cellmediated cytotoxicity by interferon-treated allogeneic lymphocytes
91. Spontaneous in vitro cytotoxicity aganist autochthonous human melamona cells
92. Lysis of fresh human B-lymphocytes- derived leukemia cells by interferon-activated natural killer (NK) cells
93. Specific T-cell-mediated killing of autologous lung tumour cells
94. Lymphocyte-mediated lysis of tumour cells in vitro: Antigen-restricted clonal and unrestricted polyclonal effects
95. Anti-viral activity induced by culturing lymphocytes with tumor-derived or visus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis
96. Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterisation of the human effector lymphocyte subpopulation
97. Modulation of target cell susceptibility to human natural killer cells by interferon
98. The uropod as an integral and specialized structure of large granular lymphocytes
99. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: Augmentation by interferon, lymphokines and endotoxin